Practice-Changing Research on Prostate Cancer Presented at ASCO 2012: With Commentary by Dr Neal Shore
This article reviews the most significant research on prostate cancer presented last month at ASCO 2012, with commentary from Dr Neal Shore.
ASCO 2012
Phase 3 Study Shows Abiraterone Improves Survival in Prostate Cancer
Abiraterone acetate (AA) plus prednisone (P) produced a statistically significant improvement in radiographic progression-free survival (rPFS) and a strong trend for increased overall survival (OS), according to the results of a study presented by a multinational team of researchers at the 2012 American Society of Clinical Oncology Annual Meeting.
Dr. Barbara Burtness at ASCO 2012 on Head and Neck Cancer
Dr. Barbara Burtness is a physician-scientist of the Fox Chase Cancer Center and an expert in the treatment of head and neck cancer.
Maintenance Gemcitabine plus Paclitaxel Chemotherapy Offers Improved Outcomes in Metastatic Breast Cancer
Maintenance chemotherapy with the combination of gemcitabine and paclitaxel (GP) following clinical response to GP is associated with improved survival times.
Weekly Paclitaxel Remains Standard Regimen for First-Line Treatment of Metastatic Breast Cancer
Neither weekly nab-paclitaxel nor ixabepilone are superior to weekly paclitaxel in patients with chemotherapy-naïve advanced breast cancer receiving bevacizumab.
ASCO: Duloxetine is Effective and Well-Tolerated for Treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Daily duloxetine therapy effective and well-tolerated for the treatment of CIPN.
ASCO: Radium-223 Prolongs Survival Time for Patients with Bone-Metastatic Castration-Resistant Prostate Cancer
Radium-223 chloride therapy significantly prolongs median OS time for men with castration-resistant prostate cancer (CRPC) bone metastasis.
Weekly Paclitaxel After Adjuvant FAC Modestly Improves DFS in High-Risk, Node-Negative Breast CA Patients
Adding weekly paclitaxel to adjuvant FAC therapy offers a modest improvement in disease-free survival for patients with high-risk, node-negative breast cancer.
Crizotinib Shows Strong Efficacy and Tolerability in Patients with ALK-positive NSCLC
Crizotinib has a strong response rate, progression-free survival (PFS), and is well tolerated in patients with ALK-positive non-small cell lung cancer (NSCLC).
Gefitinib Offers Survival Benefit for Advanced NSCLC with EGFR Mutation
First-line gefitinib for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation offers survival benefit.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...